IMC Chicago
IBRX icon

IMC Chicago’s ImmunityBio IBRX Stock Holding History

IMC Chicago’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.97M Buy
+257,300
New +$1.76M ﹤0.01% 2585

Other funds holding IBRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

IMC Chicago's IBRX Position: Q1 2026 in Review

IMC Chicago opened a new position in ImmunityBio (IBRX) in Q1 2026: 97,148 shares worth $745K. The stake represents ﹤0.01% of the portfolio and ranks #3585 among its holdings.

386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

  • IMC Chicago held 97,148 shares of ImmunityBio worth $745K as of Q1 2026.
  • ImmunityBio was a new IMC Chicago position in Q1 2026.
  • ImmunityBio made up ﹤0.01% of IMC Chicago's portfolio in Q1 2026, its #3585 holding.
  • 386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on IMC Chicago's 13F filing for Q1 2026, filed 5 May 2026.